| Here's Why Novartis (NVS) is a Strong Value Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-05-16 14:46:21 |
Czytaj oryginał (ang.) |
| Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock? |
Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-05-15 17:05:15 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Novartis (NVS) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-05-15 14:45:46 |
Czytaj oryginał (ang.) |
| New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline |
Basel, May 15, 2025 – Novartis will present data from 60 company or investigator sponsored abstracts that have the potential to change clinical practice, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2025 Congress. |
globenewswire.com |
2025-05-15 13:00:00 |
Czytaj oryginał (ang.) |
| Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices |
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices. |
youtube.com |
2025-05-12 16:36:24 |
Czytaj oryginał (ang.) |
| Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet |
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach. |
seekingalpha.com |
2025-05-12 16:30:03 |
Czytaj oryginał (ang.) |
| Novartis to keep making malaria drugs if orders dry up amid aid cuts |
Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of global health told Reuters in an interview. |
reuters.com |
2025-05-12 07:19:26 |
Czytaj oryginał (ang.) |
| Here's Why Novartis (NVS) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-05-09 14:55:56 |
Czytaj oryginał (ang.) |
| Pressure is still on the pharma sector, says Mizuho's Jared Holz |
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector. |
youtube.com |
2025-05-08 23:23:04 |
Czytaj oryginał (ang.) |
| BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion |
BioNTech SE BNTX on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02. |
benzinga.com |
2025-05-05 19:49:24 |
Czytaj oryginał (ang.) |
| Novartis (NVS) is a Great Momentum Stock: Should You Buy? |
Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2025-05-05 17:05:44 |
Czytaj oryginał (ang.) |
| Why Novartis (NVS) is a Great Dividend Stock Right Now |
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? |
zacks.com |
2025-05-05 16:50:27 |
Czytaj oryginał (ang.) |
| BioNTech says Novartis executive Zapata-Gomez to become CFO |
German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1. |
reuters.com |
2025-05-05 10:34:19 |
Czytaj oryginał (ang.) |
| Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million |
Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion. |
benzinga.com |
2025-04-30 15:22:41 |
Czytaj oryginał (ang.) |
| Why Novartis (NVS) is a Top Value Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-04-30 14:46:30 |
Czytaj oryginał (ang.) |
| These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar |
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. |
zacks.com |
2025-04-30 13:50:39 |
Czytaj oryginał (ang.) |
| Novartis: Guidance 2025 Raised To Top End Of Prior Range - Buy Confirmed |
Novartis' Q1 2025 results validate our investment thesis. They showcase double-digit sales growth and robust margins, reinforcing our overweight position. Novartis announced a $23 billion US investment, bolstering our positive outlook amid pharma tariff uncertainties. It also raised its FY 2025 outlook. Despite patent expirations, Novartis' strong cash flow, ongoing buyback, and low-risk profile support our continued buy rating. |
seekingalpha.com |
2025-04-30 13:46:04 |
Czytaj oryginał (ang.) |
| Adakveo Market Epidemiology, Pipeline Analysis, Market Insights & Forecasts Report 2025, with Focus on Novartis |
In-depth Adakveo market analysis highlights its size, growth potential, and segmentation, covering major regions and countries. Rising sickle cell disease prevalence, increasing healthcare expenditure, and innovative treatments are driving growth. Novartis AG leads, with North America as the largest market and Asia-Pacific fastest-growing. In-depth Adakveo market analysis highlights its size, growth potential, and segmentation, covering major regions and countries. Rising sickle cell disease prevalence, increasing healthcare expenditure, and innovative treatments are driving growth. Novartis AG leads, with North America as the largest market and Asia-Pacific fastest-growing. |
globenewswire.com |
2025-04-30 13:38:00 |
Czytaj oryginał (ang.) |
| Novartis to Acquire Regulus in $1.7 Billion Deal |
With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus. |
wsj.com |
2025-04-30 11:50:00 |
Czytaj oryginał (ang.) |
| Novartis to buy Regulus Therapeutics for up to $1.7 billion |
Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday. |
reuters.com |
2025-04-30 11:25:03 |
Czytaj oryginał (ang.) |
| Why Novartis Remains A 'Buy' After Beating Expectations Again |
At the end of January, Novartis pleasantly surprised me with its financial results for Q4 2024, which were achieved, in part, due to the strong performance of its oncology franchise. So, sales of Pluvicto, a medication for the treatment of prostate cancer, reached $351 million in the fourth quarter of 2024, an increase of 28.6% year-on-year. Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. |
seekingalpha.com |
2025-02-27 12:09:34 |
Czytaj oryginał (ang.) |
| Syngenta acquires genetic repository from Novartis to boost biologic crop protection |
Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and genetic strains from drugmaker Novartis to further boost development of biologic crop protection. |
reuters.com |
2025-02-26 06:39:50 |
Czytaj oryginał (ang.) |
| Sandoz family foundation offers $3 billion worth of Novartis shares |
Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 billion in an accelerated bookbuilt offering, according to the bookrunner. |
reuters.com |
2025-02-25 15:55:00 |
Czytaj oryginał (ang.) |
| Here's Why Novartis (NVS) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-02-25 12:50:43 |
Czytaj oryginał (ang.) |
| Novartis Invests $7.5M to Promote Early Prostate Cancer Testing in Vulnerable Communities |
Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for prostate cancer in vulnerable communities. |
youtube.com |
2025-02-20 09:41:06 |
Czytaj oryginał (ang.) |
| Novartis: Strong Execution With A P/E Discount |
Q4 2024 results exceeded expectations with 16% net sales growth and a 55% increase in operating income, supporting Novartis' EPS growth trajectory. The acquisition of Anthos Therapeutics and strategic investments in R&D confirmed our thesis on Novartis' new pure play as an innovative medicines leader. Novartis' strong FCF generation, supportive dividend yield, and ongoing buyback make it a buy. The company also trades below its peer average multiple. |
seekingalpha.com |
2025-02-16 02:02:08 |
Czytaj oryginał (ang.) |
| Novartis: Just What The Doctor Ordered |
Novartis' robust drug pipeline and strong financials, including an AA- credit rating, support an 11% annual return expectation by 2027. The company's diverse blockbuster portfolio and strategic cost management drove a 15.1% sales increase and 29% EPS growth in Q4 2024. Novartis' shares are undervalued by 11%, offering a 33% cumulative return potential through 2027, with a secure and growing 3.5% dividend yield. |
seekingalpha.com |
2025-02-14 09:30:00 |
Czytaj oryginał (ang.) |
| Novartis to buy Anthos Therapeutics in $3.1bn deal |
Novartis AG (ADR) (NYSE:NVS) has agreed to buy Anthos Therapeutics in a deal worth up to $3.1 billion. The Swiss drugmaker will pay $925 million upfront, with potential milestone payments of $2.15 billion. |
proactiveinvestors.co.uk |
2025-02-11 05:27:40 |
Czytaj oryginał (ang.) |
| Novartis agrees to acquire Anthos for up to $3.1 bln |
Novartis has agreed to acquire Anthos Therapeutics, a developer of a new generation of blood thinners it launched five years ago with backing from the Swiss pharmaceutical giant. |
reuters.com |
2025-02-11 03:41:44 |
Czytaj oryginał (ang.) |
| Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront |
Basel, February 11, 2025 – Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company with abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The transaction, which is subject to customary closing conditions, is fully in line with Novartis' growth strategy and therapeutic area focus, leveraging the company's strength and expertise in the cardiovascular area. |
globenewswire.com |
2025-02-11 03:15:00 |
Czytaj oryginał (ang.) |
| Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock? |
NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors already owning the stock can stay invested. |
zacks.com |
2025-02-06 12:51:26 |
Czytaj oryginał (ang.) |
| Why Novartis (NVS) is a Top Momentum Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-02-06 12:51:10 |
Czytaj oryginał (ang.) |
| Here's Why Novartis (NVS) is a Strong Value Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-02-05 12:41:36 |
Czytaj oryginał (ang.) |
| 2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond |
If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company's underlying business would almost certainly come ahead of its yield. However, the two aren't mutually exclusive. |
fool.com |
2025-02-03 10:32:00 |
Czytaj oryginał (ang.) |
| Novartis is considering further acquisitions to drive growth, CEO says |
Novartis CEO Vas Narasimhan weighs in on the impact of the new U.S. administration and artificial intelligence on the pharmaceutical industry, as well as the possibility of further acquisitions. |
youtube.com |
2025-02-03 02:30:08 |
Czytaj oryginał (ang.) |
| Novartis Posts Q4 Earnings and Sales Beat, Shares Gain |
NVS' fourth-quarter earnings and sales beat estimates. Based on the strong momentum of the company? |
zacks.com |
2025-01-31 16:21:11 |
Czytaj oryginał (ang.) |
| Novartis AG (NVS) Q4 2024 Earnings Call Transcript |
Novartis AG (NVS) Q4 2024 Earnings Call Transcript |
seekingalpha.com |
2025-01-31 14:20:15 |
Czytaj oryginał (ang.) |
| Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-01-31 12:35:35 |
Czytaj oryginał (ang.) |
| Swiss pharma giant Novartis posts better-than-expected fourth-quarter sales |
Swiss pharmaceutical giant Novartis on Friday reported better-than-expected sales in the fourth quarter, but falling short of its own guidance over the full-year stretch. Fourth-quarter net sales rose 16% on a constant currency basis to $13.2 billion, compared to the $12.795 billion estimated by analysts in an LSEG poll. |
cnbc.com |
2025-01-31 07:07:08 |
Czytaj oryginał (ang.) |
| Novartis CEO says U.S. exit from global health programmes to affect millions |
The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization and related programmes risks harming millions of people worldwide. |
reuters.com |
2025-01-31 07:00:34 |
Czytaj oryginał (ang.) |
| Novartis' Gene Therapy Meets Primary Endpoint in SMA Study |
NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal. |
zacks.com |
2024-12-31 16:56:09 |
Czytaj oryginał (ang.) |
| Here's Why Novartis (NVS) is a Strong Growth Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-31 13:01:23 |
Czytaj oryginał (ang.) |
| Novartis gene therapy helps children with rare muscle disorder in study |
Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle disorder that leaves patients too weak to walk, talk and swallow. |
reuters.com |
2024-12-30 13:01:20 |
Czytaj oryginał (ang.) |
| Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA |
Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onasemnogene abeparvovec (OAV101 IT) OAV101 IT is the first investigational gene therapy to provide clinical benefit in treatment-naïve patients with SMA aged two and older with a positive risk benefit profile Novartis plans to share results with regulatory agencies in 2025 with the aim to make OAV101 IT available to help patients with SMA in need Basel, [December 30, 2024] – Novartis today announced positive topline results from the Phase III STEER study. |
globenewswire.com |
2024-12-30 02:45:00 |
Czytaj oryginał (ang.) |
| Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules |
A U.S. appeals court on Friday revived a whistleblower lawsuit accusing the Swiss drugmaker Novartis of paying illegal kickbacks to doctors to induce them to promote its blockbuster multiple sclerosis drug Gilenya. |
reuters.com |
2024-12-27 13:19:55 |
Czytaj oryginał (ang.) |
| Buy 5 Large-Cap Laggards of 2024 Likely to Surge in the Near Term |
These five laggards of this year have double-digit upside left in the near term. They are: UBER, NVS, RYAAY, OKTA, BAH. |
zacks.com |
2024-12-23 10:50:19 |
Czytaj oryginał (ang.) |
| Some 330 jobs hit as Novartis closes Morphosys, WiWo reports |
Swiss pharmaceutical group Novartis is winding up the German biotech company Morphosys, which it acquired at the beginning of the year, German news outlet WirtschaftsWoche reported on Thursday, saying 330 jobs would be affected. |
reuters.com |
2024-12-19 07:21:06 |
Czytaj oryginał (ang.) |
| BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions |
Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging |
globenewswire.com |
2024-12-18 11:00:00 |
Czytaj oryginał (ang.) |
| NVS vs. LLY: Which Stock Should Value Investors Buy Now? |
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors? |
zacks.com |
2024-12-17 14:41:09 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing Novartis (NVS) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-12-17 12:40:33 |
Czytaj oryginał (ang.) |
| Novartis: Time To Increase |
Novartis faces headwinds from Kisqali patent litigation and Entresto competition, but clinical advancements and increased mid-term sales guidance support our Buy rating. Key growth drivers include higher investments in R&D and strategic early stake acquisitions. The CEO's focus on cash generation, dividend growth, and share buybacks provides downside protection and supports EPS growth ahead of consensus. |
seekingalpha.com |
2024-12-13 09:28:16 |
Czytaj oryginał (ang.) |
| The Zacks Analyst Blog Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI Technology |
Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI Technology are included in this Analyst Blog. |
zacks.com |
2024-12-13 05:15:16 |
Czytaj oryginał (ang.) |
| Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer |
Basel, December 10, 2024 – Novartis today announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqali® (ribociclib) that underscore the extended efficacy beyond the duration of treatment in combination with endocrine therapy (ET). Results showed a sustained reduction in distant recurrence of 28.5% (HR=0.715; 95% CI 0.604-0.847; nominal P |
globenewswire.com |
2024-12-10 11:00:00 |
Czytaj oryginał (ang.) |
| Novartis Announces Positive Results From Late-Stage Study on Fabhalta |
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 therapies. |
zacks.com |
2024-12-09 16:21:16 |
Czytaj oryginał (ang.) |
| Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML |
Basel, December 8, 2024 – Novartis today announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with Scemblix® (asciminib) showing superior major molecular response (MMR) rates at week 961. The study compared the MMR rate of Scemblix to investigator-selected standard-of-care (SoC) tyrosine kinase inhibitors (TKIs) (imatinib, nilotinib, dasatinib and bosutinib) and to imatinib alone in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) at the week 96 evaluation, the study's key secondary endpoints1. The longer-term results showed an increasing difference in Scemblix MMR rate vs. SoC, vs. imatinib and vs. 2G TKIs (nilotinib, dasatinib and bosutinib)1. Results were presented at the 66th American Society of Hematology Annual Meeting & Exposition (ASH)1. |
globenewswire.com |
2024-12-08 14:30:00 |
Czytaj oryginał (ang.) |
| 12 High-Yield Dividend Aristocrats To Weather The Coming 2025 Storm In Style |
The S&P is up almost 28% in 2024, and many investors worry about a melt-up followed by a sharp correction like in 2022 or 2018. A 2025 market correction is likely, but low-volatility, high-yield Dividend Aristocrats offer a better alternative to the traditional 60-40 portfolio and S&P. These 12 Aristocrats provide a 3.2% yield, 14% discount, 22% upside potential next year, and 10% long-term income growth consensus, while being 54% lower volatility than the S&P. |
seekingalpha.com |
2024-12-07 09:00:00 |
Czytaj oryginał (ang.) |
| New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy |
Basel, December 6, 2024 – Novartis today announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were switched from anti-C5 therapies (Hb ≥10g/dL following treatment with eculizumab or ravulizumab)1. After 24 weeks of treatment with Fabhalta, the average Hb level improved versus baseline1. |
globenewswire.com |
2024-12-06 03:15:00 |
Czytaj oryginał (ang.) |
| Novartis cannot block generic of best-selling heart drug, US appeals court says |
Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' blockbuster heart drug Entresto. |
reuters.com |
2024-12-04 14:07:04 |
Czytaj oryginał (ang.) |
| Why Novartis (NVS) is a Top Growth Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-04 12:51:33 |
Czytaj oryginał (ang.) |
| Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion |
NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug. |
zacks.com |
2024-12-03 16:40:24 |
Czytaj oryginał (ang.) |